ArticleHealth science reports2024
The global incidence, mortality, and burden of uterine cancer in 2019 and correlation with SDI, tobacco, dietary risks, and metabolic risk factors: An ecological study.
Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Shifting Cancer Landscapes in Korea: Divergent Incidence Trajectories, Sex-Specific Burdens, and Projected Case Counts for 24 Major Cancer Types from 1999 to 2023, with Forecasts to 2030.Current oncology (Toronto, Ont.) · 2026Article
- Global Burden of Premenstrual Syndrome and Uterine Fibroids in Women of Reproductive Age (1990-2023) and Projections to 2050: An Analysis of the Global Burden of Disease Study 2023.Health science reports · 2026Article
- Synergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells.Scientific reports · 2026Article
- The role of the microbiome in gynecological cancers: implications for diagnosis and treatment.Frontiers in immunology · 2026Review
- Transvaginal ultrasound-detected endometrial echogenicity heterogeneity in diagnosing endometrial carcinoma: risk factors and nomogram-based prediction model.Frontiers in oncology · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- Comparative outcomes of laparoscopic versus robotic-assisted laparoscopic techniques in the surgical staging of endometrial cancer: A systematic review and meta-analysis.Gynecologic oncology reports · 2025Review
- First Look at Chemopreventive Properties ofInternational journal of molecular sciences · 2025Article
- METTL3 stabilizes DDX17 mRNA via IGF2BP2-mediated m6A modification to suppress endometrial cancer progression.Clinical and experimental medicine · 2025Article
- Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.Journal of health, population, and nutrition · 2025Article
- Burden of risk factors attributable to Alzheimer's disease and other dementia and its relationship with the Socio-Demographic index in Asia.BMC neurology · 2025Article
- Genetic analysis of uterine lavage fluids to identify women at high risk of endometrial cancer.BMC research notes · 2025Article
- Article
- Assessment of Cyclin D1 Expression: Prognostic Value and Functional Insights in Endometrial Cancer: In Silico Study.International journal of molecular sciences · 2025Article
- Review
- Mortality of Three Major Gynecological Cancers in the European Region: An Age-Period-Cohort Analysis from 1992 to 2021 and Predictions in a 25‑Year Period.Annals of global health · 2025Article
- Mechanisms by which obesity regulates inflammation and anti-tumor immunity in cancer.Biochemical and biophysical research communications · 2024Review
- Global trend of cervical cancer among women aged 55 and older from 2010 to 2019: An analysis by socio-demographic index and geographic regions.Aging medicine (Milton (N.S.W)) · 2024Article
- Diode Laser-Based Photoacoustic Imaging for the Features of Benign and Malignant Uterine Tumors.Journal of lasers in medical sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Endometrial cancer (EC) is the sixth most common cancer among women worldwide. Since global studies are based on awareness of the incidence trend, mortality, geographical diversity, and level of social development and income of countries, this study was conducted to investigate the trend of uterine cancer (UC) in the world in 2019. Methods: Age-standardized rates (ASR) of incidence, deaths, prevalence, and disability-adjusted life years (DALYs) of UC, as well as targeted risk factors, were extracted from the Global Burden of Disease (GBD) online database 2019. Pearson correlation coefficient and SPSS 16 were used to calculate the correlation between risk factors and ASR of epidemiological indicators. Statistical significance was considered as Results: In 2019, the age-specific incidence and death rate of UC was peaking at 60-64 and 65-69 years, respectively. The highest age-standardized incidence rate per 100,000 people for UC has been reported in the Northern Mariana Islands, high sociodemographic index (SDI) countries, World Bank High-Income category, Europe continent and among World Health Organization (WHO) regions were found in the European Region. The highest age-standardized death rate per 100,000 people for UC has been reported in Grenada, high SDI countries, the World Bank High-Income category, Europe continent, and among WHO regions found in the European Region. In 2019, the age-standardized DALYs rate was 53.54 per 100,000 inhabitants, of which 48.49 cases were related to years of life lost (YLLs) and 5.05 cases were related to years lived with disability. Conclusion: According to GBD-2019, the highest incidence, mortality, and DALY of UC are in Europe. The evidence and traces of diversity can be seen in the inequalities of UC. Race, ethnicity, economic status, level of education and awareness, co-morbidities, access, grade, and histological type of tumor are the most important causes of this inequality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.